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component of cell-mediated cytotoxicity, since GzmB-
deficient CTLs cannot rapidly induce apoptosis in their
targets (Heusel et al., 1994; Shresta et al., 1995).
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-8, -9, and -10) in vitro and in vivo (Darmon et al., 1995,
1996; Chinnaiyan et al., 1996; Quan et al., 1996; Shi et
al., 1996; Medema et al., 1997). In addition, CTLs induce
Summary the activation of caspase-3 in their targets in a process
that requires GzmB, suggesting that GzmB may cause
Granzyme B (GzmB) is a component of cytotoxic lym- apoptosis by activating one or more of the caspases
phocyte granules that can rapidly initiate apoptosis in (Darmon et al., 1996; Medema et al., 1997). However,
target cells. While several procaspases are cleaved there is also conflicting evidence that suggests that
and activated by GzmB, the absolute requirement of GzmB may not rely solely upon caspase activation to
caspase activation for GzmB-induced apoptosis is inflict target cell death (Sarin et al., 1997; Talanian et al.,
controversial. In this report, we demonstrate that 1997; Andrade et al., 1998; Trapani et al., 1998; Yang et
GzmB can initiate apoptosis in the absence of cas- al., 1998; MacDonald et al., 1999). Thus, the requirement
pase-3 activity by directly cleaving DFF45/ICAD to lib- of caspase activation for GzmB-induced apoptosis re-
erate activated DFF40/CAD. DFF45/ICAD cleavage oc- mains controversial.
curs less efficiently in cells that lack caspase-3 Two independent groups have recently identified a
activity, suggesting that the caspases normally am- nuclease, known as caspase-activated DNase (CAD,
plify the GzmB death signal. DFF45/ICAD-deficient also known as DFF40), that appears to be directly re-
sponsible for DNA fragmentation, one of the hallmarksmouse embryo fibroblasts are partially resistant to
of apoptosis. CAD forms a heterodimer with ICAD (inhib-GzmB-induced death, demonstrating the biological
itor of CAD, also known as DFF45) in the nucleus, whereimportance of DFF45/ICAD for GzmB-mediated apo-
CAD is retained in its inactive form (Liu et al., 1997, 1998;ptosis.
Enari et al., 1998, 1998; Sakahira et al., 1998). When a
cell receives a death signal, caspase-3 is activated, and
Introduction it in turn cleaves DFF45/ICAD, dismantling its inhibitory
activity and facilitating the assembly of CAD into its
Cytotoxic lymphocytes (activated CD41 and CD81 T active form. Consequently, activated CAD can initiate
lymphocytes, natural killer [NK] cells, and lymphokine chromatin condensation and DNA fragmentation. Re-
activated killer [LAK] cells) play an essential role in the cently, Xu and Wang and colleagues have generated
clearance of virus-infected cells and tumor cells and in DFF45/ICAD-deficient mice (Zhang et al., 1998). While
the development of graft versus host disease (GvHD) these mice show no developmental abnormalities, some
cell types in these mice have a reduced ability to un-(Graubert et al., 1997; Shresta et al., 1998). CD81 T cells,
dergo DNA fragmentation in response to apoptotic stim-NK cells, and LAK cells predominantly utilize the granule
uli and are partially resistant to apoptosis-induced bothexocytosis pathway to induce the death of their target
in vitro and in vivo (Zhang et al., 1999). These studiescells. The current model of this pathway suggests that
established an essential role of the CAD/ICAD complexwhen cytotoxic effector cells recognize their targets,
for DNA fragmentation during apoptosis.their granules migrate toward this site of contact and
In this report, we have demonstrated that GzmB-secrete their contents directly onto the target cell. One
mediated apoptosis can proceed independent of cas-of the granule components, perforin, is responsible for
pase-3 activity. We have shown that GzmB cleavesproperly trafficking a series of granule proteases, known
DFF45/ICAD to activate CAD in vitro and that wild typeas the granzymes, into the target cells, where the gran-
CTLs (but not GzmB2/2 CTLs) rapidly cause the cleavagezymes deliver the lethal apoptotic ªhitsº (reviewed in
of DFF45/ICAD in susceptible target cells. Furthermore,Shresta et al., 1998). Granzyme B (GzmB) is an essential
in target cells pretreated with peptide caspase inhibi-
tors, GzmB can still induce DFF45/ICAD processing and
DNA fragmentation, albeit less efficiently. Finally, we§ To whom correspondence should be addressed (e-mail: timley@
im.wustl.edu). have shown that DFF45/ICAD-deficient cells are partially
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Figure 1. A Cellular Death Assay Dependent upon Active rGzmB and Perforin
(A) (Top panel) YAC1 target cells (105) were treated with a fixed dose (15 mg) of WT LAK extract, perforin-deficient extract, or purified perforin
(1.3 mg) plus increasing doses of rGzmB (0±2 mM) for 2 hr at 378C. At the end of the assay, cells were replated in complete media, and cellular
viability was assessed 16 hr later via trypan blue exclusion and morphology. The relative number of viable cells was calculated at 16 hr by
dividing the number of viable cells after GzmB treatment by the number of viable cells in untreated samples. The data shown are one
representative experiment from a total of four with similar results. Error bars represent standard deviations. Note that cells treated with purified
perforin or WT LAK extract plus rGzmB show a similar dose-dependent decrease in cell viability.
(Bottom panel) At the end of the 2 hr assay, genomic DNA was harvested from cells treated with LAK extract plus varying concentrations of
rGzmB. Genomic DNA was prepared as described in the Experimental Procedures.
(B) (Top panel) YAC1 target cells were treated with LAK extract plus increasing doses of rGzmB, the inactive mutant rGzmBS183A, or rGzmA
for 2 hr. The cells were replated and analyzed for viability. Note that only cells treated with active rGzmB demonstrated a loss of viability.
This experiment was repeated three times with similar results.
(Bottom panel) Genomic DNA was harvested from 2 3 105 cells treated with LAK extract plus 2 mM rGzmB, rGzmBS183A, or rGzmA for 2 hr.
DNA fragmentation was analyzed as described in the Experimental Procedures.
resistant to GzmB-mediated apoptosis. Collectively, plus increasing concentrations of recombinant active
GzmB (rGzmB) for 2 hr (Pham et al., 1998), and platedthese data demonstrate that GzmB can directly process
DFF45/ICAD in target cells and suggest that this path- in complete media for an additional 16 hr (ªplating
assayº). In either case, a similar amount of death oc-way is physiologically important for CTL-induced target
cell death. curred at each concentration of rGzmB, as measured
by cell morphology and trypan blue exclusion 16 hr after
treatment (Figure 1A, top panel). In contrast, cellsResults
treated with LAK extract alone or rGzmB alone exhibited
no decrease in cellular viability, even at the highest con-Establishing a GzmB-Dependent Cellular
centrations of rGzmB used. LAK extracts derived fromDeath Assay
perforin2/2 mice could not support GzmB-mediatedIn order to delineate the mechanism of GzmB-mediated
apoptosis, demonstrating that the perforin in the LAKapoptosis, we established a cellular death assay that is
extracts is essential for mediating GzmB entry and celldependent upon the activities of GzmB and perforin.
death (Figure 1A, top panel). Similar data were obtainedWe generated protein extracts from LAK cells (which
using two other target cell lines (P815 and TA3, datacontain granzymes and perforin in their granules) as a
not shown). LAK extracts derived from GzmB-deficientsource of perforin (Shresta et al., 1999) or purified per-
mice could also effectively support cell death in theforin from these extracts. YAC1 target cells were treated
with either whole LAK extracts or with purified perforin, presence of rGzmB (data not shown). We do not yet
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understand why WT LAK extract by itself (which con- (for rGzmB) or DEVDAMC (for rCaspase-3). As shown
tains GzmB) fails to cause target cell apoptosis; the in Figure 2B, as little as 10 mM of each fmk-peptide
GzmB present in this LAK extract may not be functional completely eliminated rCaspase-3 activity, while no inhi-
in our death assay. bition of rGzmB activity was detected at concentrations
We also correlated cell viability with DNA fragmenta- up to 100 mM.
tion, as a marker of apoptosis. Cells were treated with Since rGzmB activated DEVD'ase activity to the great-
LAK extract plus increasing concentrations of rGzmB est extent, we analyzed its ability to be inhibited by the
for 2 hr. Genomic DNA was immediately harvested and fmk peptides in our target cells. As shown in Figure
analyzed on ethidium stained agarose gels. Only those 2C, DEVD'ase activity was completely inhibited in cells
cells treated with LAK extract plus rGzmB displayed pretreated with 10±100 mM of BDfmk, ZVADfmk, or
significant nucleosomal laddering of genomic DNA (Fig- DEVDfmk. Similar results were obtained for cellular
ure 1A, bottom panel, lanes 6±8). As predicted by the AEVD'ase activity, although higher concentrations of in-
plating assay, cells treated either with LAK extract alone, hibitors were required to reduce AEVD'ase activity to
rGzmB alone, or perforin-deficient extract plus rGzmB background levels (data not shown).
displayed no detectable DNA laddering (lanes 2, 9±11). We next investigated whether rGzmB could kill target
To establish that GzmB's proteolytic activity was re- cells pretreated with the fmk peptides. rGzmB can in-
quired to cause death, we generated an inactive mutant duce apoptosis in target cells pretreated with 10±100
form of rGzmB, rGzmBS183A, where the active site ser- mM BDfmk, ZVADfmk, or DEVDfmk, as efficiently as in
ine 183 was mutated to an alanine. This point mutation untreated cells (Figure 2D; data not shown). Cells that
in GzmB's catalytic pocket severely attenuated its ac- were pretreated with caspase inhibitors alone, and then
tivity, as measured by cleavage of a specific pep- replated, displayed no decrease in viability (data not
tide substrate (data not shown; Caputo et al., 1994). shown). In addition, when we fixed the concentration of
rGzmBS183A was incapable of causing cell death (Fig- inhibitors at 45 mM and treated cells with increasing
ure 1B, top panel), suggesting that cleavage of cellular doses of rGzmB, we found that at every dose analyzed,
substrates was critical for death induction. In addition, cells pretreated with the caspase inhibitors were sus-
we utilized another active recombinant granzyme, ceptible to GzmB-mediated apoptosis (Figure 2E).
rGzmA, to test the specificity of the system. As shown Previous studies have suggested that GzmB-induced
in Figure 1B (top panel), rGzmA plus LAK extracts did not DNA fragmentation also requires caspase activation
kill YAC1 target cells with these incubation conditions. (Andrade et al, 1998; Atkinson et al., 1998; Sarin et al.,
Once again, DNA fragmentation could be detected with 1998; Trapani et al., 1998). We therefore assessed
active rGzmB plus perforin sufficient extracts but not GzmB-induced nucleosomal laddering in cells pre-
with rGzmA or rGzmBS183A (Figure 1B bottom panel, treated with ZVADfmk and found that rGzmB can still
lane 3 versus lanes 4 and 5). induce DNA fragmentation but with less efficiency than
in target cells that were not exposed to the caspase
GzmB Can Induce Apoptosis in the Absence inhibitor (Figure 2F, lanes 1±4). Similar results were ob-
of Measurable Caspase Activity served at 4, 6, and 8 hr (lanes 5±8, and data not shown).
Although multiple lines of evidence suggest that GzmB Although DEVD'ase activity was inhibited in the pres-
can process and activate members of the caspase fam- ence of ZVADfmk at 2 hr, by 8 hr we could not demon-
ily, it remains controversial whether caspases are re- strate any cellular DEVD'ase activity, with or without the
quired for GzmB-induced apoptosis (Sarin et al., 1998; caspase inhibitors (data not shown).
Trapani et al., 1998). We first assessed which caspases Finally, we wished to assess the role of caspase-3 for
were activated in response to GzmB treatment of target GzmB-mediated apoptosis using caspase-32/2 target
cells. We surveyed a panel of fluorogenic peptide cells. We generated murine embryonic fibroblasts
caspase substrates (AEVDAFC, DEVDAMC, LEHDAFC,
(MEFs) from caspase-32/2 mice (Kuida et al., 1996), as
LETDAFC, YVADAFC, and VADAFC) and determined
well from their wild-type littermate controls, to use as
that only DEVD'ase (measuring caspase-2, -3 or -7) and
target cells in our plating assay. Caspase-32/2 MEFsAEVD'ase (measuring caspase-6, -8, or -9) activities are
were as susceptible to GzmB-induced death as theirinduced in YAC1 target cells treated with rGzmB (Figure
wild-type counterparts (Figure 2G). We analyzed several2A; data not shown).
wild-type and caspase-32/2 MEF preparations derivedFlouromethylketone-based peptides specifically in-
from independent embryos and observed similar sus-hibit the activities of cysteine proteases (e.g., caspases)
ceptibilities in each experiment (data not shown).but are unable to efficiently inhibit serine proteases (e.g.,
granzymes) because of the structure of the fmk moiety
rDFF45/ICAD Is a Direct Substrate(J. Talhouk, Enzyme Systems Products, personal com-
of rGzmB In Vitromunication). We therefore employed the peptide inhibi-
Our data suggest that GzmB may directly process thetors BocDfmk, ZVADfmk, and DEVDfmk to assess the
critical death substrates that lead to DNA fragmentationrole of the caspases for GzmB-mediated apoptosis.
during apoptosis. One potential substrate is DFF45/Both BDfmk and ZVADfmk are broad-spectrum caspase
ICAD. We hypothesized that GzmB may be able to di-inhibitors, while DEVDfmk inhibits caspase-3-like prote-
rectly process DFF45/ICAD in a similar fashion as cas-ases. To establish that these peptides specifically inhib-
pase-3, and in doing so, bypass the caspase-3 require-ited caspase activity, we first pretreated rGzmB and
ment for the induction of DNA fragmentation. To assessrCaspase-3 with increasing concentrations of the three
whether DFF45/ICAD is a direct substrate of GzmB inpeptide inhibitors and measured residual enzymatic ac-
tivity with the peptide substrates, Boc-AlaAlaAspSBzl vitro, we incubated rGzmB with recombinant DFF45/
Immunity
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Figure 2. Caspase-3 Activity Is Not Required for GzmB-Induced Apoptosis
(A) GzmB-induced caspase activation in target cells. YAC1 cells (3 3 105) were treated with 30 mg LAK extract plus 2 mM rGzmB (or rGzmBS183A)
for an hour. Cells were lysed, and extracts were incubated with DEVDAMC, AEVDAFC, or YVADAFC for 30 min. Caspase activation was
DFF45/ICAD Is a Substrate of GzmB
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ICAD and analyzed cleavage products using Western experiment, we analyzed DFF45/ICAD processing after
2 hr of incubation of effectors and targets. In this mixtureblot analysis. We found that active rGzmB (but not
rGzmBS183A) can rapidly process DFF45/ICAD into p30 of wild-type LAK effectors and targets, we detected
DFF45/ICAD cleavage into its p30 form (Figure 4B), butand p11 forms (Figure 3A).
We next analyzed whether GzmB could process GzmB2/2 LAKs were unable to induce DFF45/ICAD pro-
cessing. After 8 hr, incubation of GzmB2/2 effectors withDFF45/ICAD that is heterodimerized with CAD in vitro.
The rCAD/ICAD heterodimer was pretreated with in- YAC1 target cells results in target cell death via the
GzmA pathway (data not shown; Shresta et al., 1999).creasing concentrations of either rCaspase-3 or rGzmB
for 2.5 hr, and then plasmid DNA was added to each However, we did not detect any processing of DFF45/
ICAD in targets after prolonged incubation with GzmB2/2sample (as a potential substrate for CAD) for another 2.5
hr. An aliquot of each sample was harvested to assess effectors, despite significant apoptosis induced by the
GzmA pathway (data not shown).DFF45/ICAD processing by Western blot analysis. As
shown in Figure 3B, rCaspase-3 efficiently processes
DFF45/ICAD into its signature forms when it is hetero-
dimerized with CAD (lanes 2±4). While rGzmB also pro- Caspase-3 and DFF45/ICAD Are Both Rapidly
Processed in Cells Undergoingcesses heterodimerized DFF45/ICAD in a dose-depen-
dent manner, higher concentrations of rGzmB are GzmB-Mediated Apoptosis
Due to the complexity of the effector:target system, itrequired to cause DFF45/ICAD processing (lanes 5±7),
and the sizes of the cleavage products in the p30 range was difficult to specifically analyze the role of the CAD/
ICAD complex during GzmB-mediated apoptosis. Weare not identical to those induced by rCaspase-3. In the
same experiment, rCaspase-3 caused CAD-dependent therefore employed our reconstituted death assay to
further assess the interplay among GzmB, caspase-3,plasmid DNA degradation, correlating with DFF45/ICAD
cleavage into its p11 form (Figure 3C, lanes 4±5). Impor- and the CAD/ICAD complex. We initially analyzed the
kinetics of caspase-3 activation by Western blot. Cellu-tantly, rGzmB can also induce plasmid degradation by
directly cleaving DFF45/ICAD and liberating CAD, but lar caspase-3 is completely processed from its p32 pro-
form into its signature p17 and p10 active forms withinthe process is less efficient than that observed with
rCaspase-3 (lanes 6±8). 1 min after delivery of rGzmB to target cells. In contrast,
the inactive mutant rGzmBS183A had no effect on cas-
pase-3 activation for up to 120 min of treatment (FigureDFF45/ICAD Is Processed in Target Cells Undergoing
CTL-Induced Apoptosis 5A). rGzmB initiates cellular DFF45/ICAD cleavage (ei-
ther directly or via activated caspase-3, see below)We next analyzed whether DFF45/ICAD is processed in
target cells undergoing CTL-induced apoptosis (Heusel within 1 min and its processing is complete within 20
min (Figure 5B). Although processed caspase-3 is stillet al., 1994). We generated both wild-type and GzmB-
deficient (GzmB2/2) LAK effectors and incubated them detectable in the target cell extracts after 120 min, pro-
cessed DFF45/ICAD is not, suggesting that the pro-with target YAC1 cells, prelabeled with 125IUdR, at in-
creasing effector to target ratios. At 2 hr, wild-type LAKs cessed form of DFF45/ICAD is rapidly degraded.
Finally, we assessed the kinetics of DNA fragmenta-efficiently induce DNA fragmentation and apoptosis in
YAC1 cells, as measured by specific 125IUdR release tion in YAC1 cells treated with LAK extract and rGzmB.
Nucleosomal laddering could be demonstrated within(Figure 4A). In contrast, GzmB-deficient LAKs are unable
to induce significant target cell 125IUdR release (Figure 10 min after delivery of rGzmB, correlating with pro-
cessing of DFF45/ICAD into its p11 form (Figure 5C;4A; Shresta et al., 1995). Using the cells from the same
measured using a spectrofluorometer. Significant DEVD'ase and AEVD'ase activities were induced by GzmB.
(B) Specific inhibition of rCaspase-3 activity by fmk peptides. 100 u rCaspase-3 or 0.2 mg rGzmB was pretreated for 30 min with increasing
concentrations of the broad-spectrum peptide caspase inhibitors, BocDfmk or ZVADfmk, or with DEVDfmk, which is specific for caspase-3-
like proteases. GzmB activity was assessed using the peptide substrate, BocAlaAlaAspSBzl, as previously described (Pham et al., 1998), and
rCaspase-3 activity was assessed using the peptide substrate, DEVDAMC. Note that only rCaspase-3 activity was inhibited by the fmk peptides.
(C) Inhibition of cellular DEVD'ase activity. YAC1 cells were pretreated with 10±100 mM BDfmk, ZVADfmk, or DEVDfmk for 30 min. The cells
were then washed, and the same protocol was performed as described in (B). Note that GzmB-induced cellular DEVD'ase activity is completely
inhibited at 10 mM of each inhibitor.
(D) GzmB-induced apoptosis in the absence of measurable caspase activity. The same protocol was performed as in (C), but at the end of
the assay the cells were replated, and viability was assessed at 16 hr. The relative number of viable cells was defined by dividing the number
of viable cells after GzmB treatment by the number of viable cells in untreated samples. Note that at each concentration, cells pretreated
with the caspase inhibitors were as susceptible to death as untreated cells. Cells treated with either inhibitor alone or vehicle alone showed
no decrease in cellular viability (data not shown).
(E) YAC1 cells were pretreated with a fixed dose (45 mM) of either ZVADfmk or DEVDfmk and then treated with increasing concentrations of
rGzmB. Cellular viability was assayed as described in (D). At every concentration of rGzmB tested, cells pretreated with the caspase inhibitors
were as susceptible to apoptosis as untreated cells.
(F) YAC1 cells were pretreated with ZVADfmk for 30 min and then treated with LAK extract plus rGzmB for either 2 or 8 hr. Genomic DNA
was harvested and analyzed for DNA fragmentation as described in the Experimental Procedures. Note that at both 2 and 8 hr, rGzmB can
induce DNA fragmentation in the presence of ZVADfmk, but with less efficiency.
(G) Caspase-3-deficient MEFs and their WT littermate controls were generated from E13.5 embryos. On the assay day, 105 MEF cells were
harvested by trypsinization, resuspended in RBC buffer, and treated with LAK extract plus 2 mM rGzmB for 2 hr at 378C. Cells were replated
in MEF media, and adherent cells were counted the next day. This experiment was performed three times with multiple sets of MEFs derived
from independent embryo pairs, with similar results.
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Figure 3. rGzmB Can Directly Process DFF45/ICAD to Liberate and Activate CAD Nuclease Activity In Vitro
(A) 1.8 mg rDFF45/ICAD was incubated alone or with 3.6 mg rGzmB or rGzmBS183A for 0±120 min at 378C. At each time point, 300 ng was
harvested, and the reaction was stopped with SDS tracking dye. At the end of the assay, the samples were electrophoresed on SDS gels,
and Western blots were performed using an anti-human DFF45/ICAD antibody (1:2000).
(B and C) Recombinant CAD/ICAD heterodimers were produced as described previously (Liu et al., 1998). Twenty microliters of the complex
was incubated alone or in the presence of increasing concentrations of rCaspase-3 or rGzmB for 2.5 hr. Two hundred nanograms of Histone
H1 and 1.5 mg of plasmid DNA were added to each sample (as a substrate for CAD) for another 2.5 hr. In (B), an aliquot of each sample was
harvested and electrophoresed on SDS gels, and Western blot analysis was performed with the anti-human DFF45/ICAD antibody. In (C), the
remaining DNA in each sample was purified and electrophoresed on a 1.5% agarose gel. Note that both rGzmB and rCaspase-3 can induce
CAD-dependent plasmid degradation but that higher concentrations of rGzmB are required to produce a similar amount of plasmid
degradation.
Janicke et al., 1998). With the more sensitive TUNEL- 4 and 5 versus lane 3). Under these conditions, all of
flow assay, we could detect DNA nicking as early as 5 the cellular procaspase-3 was cleaved into its active
min (18% of cells were TUNEL positive), and by 120 min, form by rGzmB treatment, as expected (data not shown).
approximately 41% of the cells were TUNEL positive As shown in Figure 6A (top panel, lane 3), DFF45/ICAD
(lane 9). Neither rGzmBS183A nor active rGzmA was able is completely processed and turned over in target cells
to cause detectable DNA fragmentation, using these treated for 2 hr with rGzmB. However, even in the pres-
conditions and times (Figure 5C; data not shown). In ence of the caspase inhibitors, rGzmB still induces pro-
addition, rGzmB plus perforin-deficient LAK extract cessing of DFF45/ICAD (lanes 4 and 5), but to a lesser
failed to induce caspase-3 activation, DFF45/ICAD extent. Similarly, we could still demonstrate GzmB-
cleavage, or DNA fragmentation (data not shown). induced DFF45/ICAD processing in the presence of up to
200 mM fmk peptides, as well as DFF45/ICAD processing
in caspase-3-deficient MEFs (data not shown). Cells pre-GzmB Induces DFF45/ICAD Cleavage and DNA
treated with the caspase inhibitors alone did not exhibitFragmentation in the Absence of Measurable
cleavage of DFF45/ICAD (lanes 7 and 8), nor did rGzmBCaspase-3 Activity
in the absence of LAK extract (lane 9). Similar resultsWe next determined the ability of GzmB to cause cellular
were demonstrated with the P815 cell line.DFF45/ICAD cleavage and DNA fragmentation in the
To correlate DFF45/ICAD processing with DNA frag-absence of measurable DEVD'ase activity. We pre-
mentation (as a measure of CAD activation), we analyzedtreated cells with 45 mM ZVADfmk or DEVDfmk and
the percentage of TUNEL-positive cells in the presenceconfirmed that both inhibitors reduced GzmB-induced
DEVD'ase activity to background levels (Figure 6A, lanes or absence of the caspase inhibitors. 45% of YAC1 cells
DFF45/ICAD Is a Substrate of GzmB
627
Figure 4. DFF45/ICAD Is Processed in Target
Cells under Attack by WT LAK Effectors but
Not GzmB-Deficient Effectors
(A) WT and GzmB2/2 LAK effectors were gen-
erated and used in an in vitro cytotoxicity
assay as previously described (Shresta et al.,
1995). Target YAC1s were prelabeled with
125IUdR and then incubated with either WT or
GzmB2/2 LAK effectors, at increasing ef-
fector:target ratios for 2 hr. Percent specific
release of 125IUdR from the target cells was
measured as described (Heusel et al., 1994).
(B) Unlabeled YAC1 targets (105) were incu-
bated with the same WT or GzmB2/2 LAK
effectors used above at increasing E:T ratios
for 2 hr at 378C. Cell extracts were made from
each sample and electrophoresed on a 10%
SDS-PAGE gel. Western blot analysis was
performed using an anti-murine DFF45/ICAD
antibody. Note that DFF45/ICAD processing
occurs in target cells incubated with WT LAK
effectors but not with GzmB2/2 effectors.
pretreated with LAK extract and rGzmB exhibited TUNEL apoptosis, we pretreated WT and DFF45/ICAD deficient
cells with ZVADfmk and then treated the cells withpositivity (Figure 6A, lane 3), whereas rGzmBS183A
caused a background level of TUNEL-positive cells (lane rGzmB. As shown in Figure 6C, inhibition of measurable
caspase-3 activity in DFF45/ICAD2/2 cells did not in-6) at 2 hr. In cells treated with 45 mM DEVDfmk or
ZVADfmk, GzmB still induced 32% and 30% TUNEL crease their resistance to GzmB-induced apoptosis.
positivity, respectively (lanes 4 and 5). Cells treated with
the caspase inhibitors alone showed background num- Discussion
bers of TUNEL-positive cells (lane 7 and 8).
In this study, we investigated the role of the caspases
and the CAD/ICAD complex as potential mediators ofDFF45/ICAD-Deficient MEFs Are Partially Resistant
to GzmB-Induced Death GzmB-induced apoptosis. Using caspase-specific pep-
tide inhibitors in our target cells (as well as caspase-3-Finally, we wanted to assess the biological relevance of
DFF45/ICAD for GzmB-mediated apoptosis. We there- deficient target cells), we have demonstrated that cas-
pase-3 activity is not required for GzmB-induced targetfore generated MEFs from DFF45/ICAD2/2 and WT lit-
termate control mice to use as target cells in the plating cell death. Since GzmB was able to bypass caspase-3
activity and still initiate DNA fragmentation, we reasonedassay (Zhang et al., 1998). Untreated DFF45/ICAD WT
and deficient MEFs were equally viable at 16 hr (Figure that GzmB may directly process a downstream sub-
strate that is involved in nuclease activation. One at-6B). However, while 80%±90% of the WT MEFs was
killed by rGzmB, 40%±50% of the DFF45/ICAD-deficient tractive target was the CAD/ICAD complex, since it is
responsible for DNA fragmentation during caspase-3-MEFs remained viable using the same conditions. Multi-
ple WT and DFF45/ICAD-deficient MEF pairs obtained induced apoptosis. Indeed, DFF45/ICAD processing oc-
curred in target cells under attack by WT LAK effectorsfrom independent embryos were analyzed for GzmB
susceptibility, and in each experiment, the results were but not GzmB-deficient effectors. We have shown that
GzmB processes DFF45/ICAD and liberates activatedconsistent (Figure 6B; data not shown). Finally, to deter-
mine whether inhibition of the caspases in DFF45/ICAD- CAD in vitro and that DFF45/ICAD is rapidly processed in
cells undergoing GzmB-induced apoptosis. In addition,deficient cells increased resistance to GzmB-mediated
Immunity
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GzmB induces DFF45/ICAD cleavage and DNA fragmen-
tation, even in the absence of measurable caspase activ-
ity. Finally, we have shown that DFF45/ICAD-deficient
MEFs are not as susceptible to GzmB-induced apo-
ptosis as their WT counterparts, which suggests that the
CAD/ICAD complex plays a significant role in GzmB-
mediated death.
Several groups have demonstrated that inhibition of
caspase-3 in target cells blocks GzmB-induced apo-
ptotic nuclear damage, suggesting that caspase-3 is
required for the death signal delivered by GzmB (Sarin
et al., 1997; Janicke et al., 1998; Trapani et al., 1998;
Yang et al., 1998). However, our data demonstrate that
GzmB-mediated DFF45/ICAD processing and DNA frag-
mentation does indeed occur in the absence of cas-
pase-3 activity, albeit much less efficiently. This dis-
crepancy may be attributable to many different system
variables among the studies, such as the source and
purity of enzymes, the granzyme delivery system used,
the time of target cell incubation, the apoptotic readout
(e.g., TUNEL, chromatin condensation, DNA fragmenta-
tion, caspase activation, etc.), and the nature of the
target cell itself. We do not know which of these vari-
ables has caused this study-to-study variation. How-
ever, in the studies described here, caspase-3 activity
is not required for GzmB-induced cell death, even
though the amount of DNA fragmentation occurring in
the absence of DEVD'ase activity is significantly less
than cells in which the caspases are fully active. There-
fore, GzmB seems to utilize the caspases to amplify its
death signal but can still initiate apoptosis in the ab-
sence of measurable caspase activity in the target cells.
The studies performed with the caspase inhibitors
were extended by the demonstration that caspase-3-
deficient MEFs are as susceptible to GzmB-mediated
death as their wild-type counterparts. Although there
are other caspase family members present in cas-
pase-32/2 MEFs, several lines of evidence suggest that
they cannot compensate for the caspase-3 deficiency.
First, in MCF-7 cells (which contain no detectable cas-
pase-3), GzmB is unable to directly process caspases-6,
-7, -8, -9, and -10 unless caspase-3 is introduced into
the cells, suggesting that the other caspases remain inert
without caspase-3 (Tang and Kidd, 1998; Yang et al., 1998).
Second, although other caspase members (e.g., cas-
pase-7) can cleave the peptide substrate, DEVDAMC
(Talanian et al., 1997a), caspase-3-deficient MEFs dem- Figure 5. Kinetics of Caspase-3 Cleavage, DFF45/ICAD Processing,
and DNA Fragmentation in YAC1 Cellsonstrate background levels of DEVD'ase activity when
treated with rGzmB (data not shown). Finally, the (A) YAC1 cells (5 3 105) were treated with fixed doses of LAK extract
plus rGzmB (or rGzmBS183A) for 0±120 min in RBC buffer. At theZVADfmk inhibitor blocks all measurable DEVD'ase ac-
indicated times, the reaction was stopped by lysing the cells. At thetivity in our target cells; in its presence, GzmB can still
end of the assay, the extracts were electrophoresed on SDS-PAGEinduce target cell DFF45/ICAD cleavage, DNA fragmen-
gels, and Western blot analysis was performed using an anti-cas-tation, and death. Therefore, the caspase-3-like prote- pase-3 (Csp3) antibody (1:3000). Note that GzmB induces cellular cas-
ases appear to be important for amplifying the GzmB pase-3 processing into its active p17 and p10 forms within 1 min.
death signal, but they are not required for the induction (B) The same protocol was performed as described in (A), but the
of apoptosis per se. These results suggest that GzmB Western blot was hybridized with an anti-murine DFF45/ICAD anti-
body. Note that GzmB initiates cellular DFF45/ICAD processingcan directly process the critical death substrates that
within 1 min and that it is completely processed by 20 min.would otherwise be targeted by caspase-3, possibly due
(C) Cells were treated as above, but at each time point, genomicto their similar aspartic acid substrate specificity.
DNA was harvested as previously described and electrophoresed
We therefore hypothesized that there must be critical on a 2% agarose gel. In addition, the percentage of FITC-TUNEL-
substrates that GzmB can directly process to induce positive cells was assessed at each time point by flow cytometry.
cell death. Because the CAD/ICAD complex is responsi- Note that DNA fragmentation was visualized at 10 min but was
ble for initiating DNA fragmentation during caspase-3- detected by the more sensitive flow-TUNEL assay within 5 min after
rGzmB delivery.mediated apoptosis, we asked whether GzmB directly
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Figure 6. Caspase-Independent DFF45/ICAD Processing and Its Biological Relevance for GzmB-Induced Apoptosis
(A) YAC1 cells (5 3 105) were pretreated with 45 mM of the peptide caspase inhibitors, ZVADfmk or DEVDfmk, and then treated with fixed
doses of LAK extract plus rGzmB, as described in Figure 5. After 2 hr, protein extracts were obtained from each sample, and caspase activity
was measured using the fluorogenic peptide substrate, DEVDAMC. DFF45/ICAD processing was determined using Western analysis (top
panel). Note that even in the absence of measurable caspase-3 activity, DFF45/ICAD can still be processed, albeit less efficiently. To analyze
the amount of DNA fragmentation induced by rGzmB in the same experiment, 3 3 106 target cells were used, and the rest of the reaction
was scaled up accordingly. After 2 hr, cells were analyzed for FITC-TUNEL positivity. Note that GzmB can induce TUNEL positivity in the
absence of measurable DEVD'ase activity.
(B) WT and DFF45/ICAD-deficient MEFs were generated from two independent sets of E13.5 day embryos. The death assay was performed
as described in Figure 2G. The percentage of viable MEFs at 20 hr was defined as the number of adherent MEFs counted/105 MEFs plated 3
100. Experiments 1 and 2 represent assays performed with two sets of WT and mutant MEFs derived from independent embryo pairs.
(C) Both WT and DFF45/ICAD-deficient MEFs were pretreated with 45 mM ZVADfmk, as described above, and the experiment was performed
as described in Figure 2G. Cells treated with the inhibitor alone or vehicle alone demonstrated no decrease in cellular viability (data not
shown). Note that DFF45/ICAD-deficient cells pretreated with the inhibitor do not show an increased resistance to GzmB-induced apoptosis.
activates CAD via processing of its inhibitor, DFF45/ Caspase activation and cleavage of various cellular
substrates have served as surrogate markers of apo-ICAD. While Wolf et al. (1999) did not detect direct activa-
tion of CAD by GzmB, we were able to clearly demon- ptosis, but it is not clear whether these events are required
for cell death. We therefore wished to demonstrate thestrate that our recombinant GzmB preparation does
cleave DFF45/ICAD (either monomeric or heterodimer- biological relevance of DFF45/ICAD by analyzing the
susceptibility of DFF45/ICAD-deficient target cells toized with CAD) and that CAD can be activated by GzmB
in vitro and in vivo. Our data suggest that rGzmB does GzmB-induced death. We found that DFF45/ICAD-defi-
cient cells are less susceptible to apoptosis than theirnot process DFF45/ICAD as efficiently as rCaspase-3,
since higher concentrations of rGzmB are required to WT counterparts. This suggests that GzmB initiates at
least one death pathway that requires DFF45/ICAD. Sim-induce a similar amount of CAD activation. However,
we do not know the relative concentrations of cas- ilarly, Zhang et al. (1999) have recently shown that
DFF45/ICAD-deficient cells are more resistant to certainpase-3 and GzmB in target cells under attack by CTL
or the rate constants of these enzymes for the DFF45/ apoptotic stimuli in vivo and in vitro, possibly due to the
lack of amplification of the apoptotic response in cellsICAD substrate. Regardless, both GzmB and caspase-3
can activate CAD by processing DFF45/ICAD, and without double-stranded DNA breaks.
Finally, DFF45/ICAD-deficient MEFs do not show anGzmB clearly utilizes caspase-3 to amplify its ability to
cleave DFF45/ICAD in target cells. increased resistance to GzmB-mediated death when
Immunity
630
processing of DFF45/ICAD, it is probably not required
for GzmB to cause target cell death. In addition, our
studies suggest that GzmB must also be able to execute
targets via a DFF45/ICAD-independent pathway. Our
future studies will attempt to define the critical sub-
strates in this alternative pathway.
Experimental Procedures
Replating and Cell Viability Assay
Recombinant murine GzmB (rGzmB) was produced and purified as
previously described (Pham et al., 1998). Mutation of GzmB's active
site Ser to Ala (rGzmBS183A) was performed with Stratagene's Site
Directed Mutagenesis Kit, and the mutant rGzmBS183A protein was
then produced and purified as described for rGzmB. Attenuated
GzmB activity was confirmed using a tetrapeptide substrate, Boc-
Ala-Ala-AspSBzl, as previously described (Caputo et al., 1994; Pham
et al., 1998).
Perforin was purified from an adherent murine NK cell line (37.12)
(MacIvor et al., 1999) that expresses abundant levels of Gzms and
perforin. LAK effector cells were generated and extracts prepared
as previously described (Shresta et al., 1999).
Target YAC1 cells (H2a) were cultured in standard K5 media
(Shresta et al., 1995) and split 1:20 2 days prior to harvest to ensure
that cells would be in log phase growth. Cells were harvested,
washed twice, and resuspended at 2 3 106/ml in RBC buffer (HBSS
containing 0.01 M Hepes [pH 7.5], 2.5 mM CaCl2, and 0.4% BSA).Figure 7. Potential Mechanisms of GzmB-Mediated Apoptosis
105 YAC1 cells were incubated at 378C for 2 hr in 100 ml total reactionSee text for details.
volume with either 15 mg of total LAK extract (as a source of perforin)
or with 1.3 mg of purified perforin, plus 0±2 mM rGzmB (or
rGzmBS183A). At the end of the incubation period, cells were gently
pelleted by centrifugation at 3000 rpm. In some experiments, thetheir endogenous caspases are inhibited. This implies
cells were resuspended in 1 ml K5 media and replated in a 24-wellthat GzmB does not require caspases to generate the
dish overnight at 378C. Cells were harvested 16±20 hr later, anddeath signal(s) that operates independently of DFF45/
viable cells were counted via exclusion of Trypan Blue and morphol-ICAD. Importantly, a significant percentage of the
ogy. In other experiments, the genomic DNA was harvested at the
DFF45/ICAD-deficient MEFs still die with rGzmB treat- end of the 2 hr to analyze DNA fragmentation. To extract genomic
ment, which predicts that additional pathways exist. DNA, cells were resuspended in 100 ml 13 Hebs plus 100 ml 2X DNA
extraction buffer (20 mM Tris, [pH 7.5], 20 mM EDTA, and 1% SDS)Although the nature of this pathway(s) is currently un-
and 100 mg Proteinase K and incubated at 528C for 1 hr. DNA wasknown, Heiben et al. (1999) and MacDonald et al. (1999)
precipitated with 1/10 volume 3 M NaOAc pH 5.5 and 2 volumeshave recently implicated the mitochondria as a target
of 100% EtOH at 2708C. DNA was pelleted by centrifugation andfor caspase-independent death induced by GzmB. The
resuspended in 13 TE plus 10 mg RNaseA overnight. The next day,
identification of this DFF45/ICAD-independent pathway DNA was electrophoresed on 2% gels and visualized by ethidium
strongly suggests that there are substrates involved in bromide staining.
For the caspase inhibition studies, rCaspase-3 (Calbiochem) ortarget cell execution that have not yet been identified.
rGzmB was pretreated with increasing concentrations of either Boc-Although activation of caspases clearly amplifies the
Dfmk, ZVADfmk, or DEVDfmk (Enzyme Systems Products, ESP) forGzmB death signal, our results demonstrate that GzmB
30 min, and then GzmB activity was measured using BocAla-can directly attack the CAD/ICAD complex in target
AlaAspSbzl, as previously described (Pham et al., 1998); for cas-
cells. This direct pathway may be important physiologi- pase-3 activity, cleavage of the peptide fluorogenic substrate,
cally, especially in light of the many recently identified Ac-DEVD-AMC (Pharmingen), was assayed exactly according to the
manufacturer's recommendation. All other peptide substrates wereviral and cellular caspase inhibitors (Deveraux et al.,
purchased from ESP and assayed according to manufacturer's pro-1997). If GzmB utilized caspase activation exclusively
tocols. For caspase activation and apoptosis studies, 1±3 3 105to cause apoptosis, cells that contain caspase inhibitors
target YAC1 cells were resuspended in 1 ml RBC buffer and thewould be resistant to CTL-mediated attack. Many vi-
caspase inhibitors, BDfmk, ZVADfmk, DEVDfmk, or the vehicle
ruses express caspase inhibitors (i.e., cowpox virus en- alone, DMSO, were added to a final concentration of 10±100 mM
coded CrmA, and baculovirus p35) to escape specific for 30 min at 378C. Cells were gently pelleted, resuspended in 100
ml RBC buffer, and the killing assay was performed as describeddeath stimuli (Quan et al., 1995; Tewari et al., 1995;
above. In some experiments, at the end of 2 hr, the cells were lysedMacen et al., 1996). In addition, tumor cells may also
in 25 ml of 1% Triton X-100 and then incubated in the appropriateupregulate endogenous cellular caspase inhibitors (i.e.,
buffer for each caspase peptide substrate.XIAP) as a mechanism to prevent programmed cell
death. This direct route from effector cell signal to target
LAK-Mediated Cytotoxicity and DFF45/ICAD Cleavagecell apoptotic machinery may provide a ªfail-safeº
For biochemical analysis of DFF45/ICAD cleavage, 105 unlabeledmechanism that supersedes the effects of cellular cas-
YAC1 targets were incubated with either WT or GzmB2/2 LAKs atpase inhibitors. As depicted in our model in Figure 7,
increasing effector to target ratios in K5 media for 2 hr at 378C. Each
GzmB probably initiates multiple death pathways to en- sample was lysed in 1% Triton buffer and loaded directly onto 10%
sure rapid and efficient elimination of the target cell. SDS-PAGE gels. Proteins were transferred to nitrocellulose, and
Western blot analysis was performed with an anti-murine DFF45/While caspase-3 (or other family members) amplifies the
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ICAD antibody (1:500) plus an anti-rabbit secondary antibody conju- both important for the development of graft-versus-host disease
after murine bone marrow transplantation. J. Clin. Invest. 100,gated to HRP (1:15000, Amersham). Blots were developed with
Pierce SuperSignal ECL. 904±911.
Heiben, J.A., Barry, M., Motyka, B., and Bleakley, R.C. (1999). Gran-
Kinetic Assays zyme B-induced loss of mitochondrial inner membrane potential
3.5 3 106 YAC1 (5 3 105 cells/time point) were incubated with 21 (Dcm) and cytochrome c release are caspase independent. J. Immu-
mg rGzmB (3 mg/time point) plus 280 mg LAK extract (40 mg/time nol. 163, 4683±4693.
point) in RBC buffer for the indicated times. At each time point, an Heusel, J.W., Wesselschmidt, R., Shresta, S., Russell, J., and Ley,
aliquot of cells was harvested and the reaction stopped by lysing T.J. (1994). Cytotoxic lymphocytes require granzyme B for the rapid
the cells and freezing the reaction. At the end of the assay, samples induction of DNA fragmentation and apoptosis in allogeneic target
were loaded onto SDS-PAGE gels and analyzed by Western blot. cells. Cell 76, 977±984.
For caspase-3 detection, we used an anti-caspase-3 antibody
Janicke, R.U., Sprengart, M.L., Wati, M.R., and Porter, A.G. (1998).
(Csp3) (IDUN pharmaceuticals) at 1:3000 plus an anti-rabbit second-
Caspase-3 is required for DNA fragmentation and morphological
ary antibody conjugated to HRP (1:5000). The FITC-TUNEL assay
changes associated with apoptosis. J. Biol. Chem. 273, 9357±9360.
was performed using the ApopTag Fluorescent Kit from Oncor, ex-
Kuida, K., Zheng, T.S., Na, S., Kuan, C-y., Yang, D., Karasuyama,actly according to their protocol.
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